June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Remaining key questions in myopia control treatments, including importance of studying diverse populations
Author Affiliations & Notes
  • Padmaja Sankaridurg
    Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia
    Brien Holden Vision Institute, Sydney, New South Wales, Australia
  • Footnotes
    Commercial Relationships   Padmaja Sankaridurg BHVI, Code C (Consultant/Contractor), EssilorLuxottica, Shamir Optical, Coopervision, Code F (Financial Support), BHVI, Code P (Patent), EssilorLuxottica, SEED Co, Oculus, SightGlass, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 14. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Padmaja Sankaridurg; Remaining key questions in myopia control treatments, including importance of studying diverse populations. Invest. Ophthalmol. Vis. Sci. 2023;64(8):14.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Presently, multiple strategies have been demonstrated to slow the progression of myopia. The use of such strategies is increasingly becoming mainstream clinical practice. However, we are becoming aware of some unique challenges when exploring and assessing newer strategies or mechanisms underlying the efficacy of these strategies. For example, their efficacy is typically assessed using randomized test and control groups, a methodology that raises questions related to duration, use of controls, applicability to other populations etc. This talk will highlight some of these important questions.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×